Stock Analysis

Tong Ren Tang Technologies Full Year 2023 Earnings: EPS Misses Expectations

Published
SEHK:1666

Tong Ren Tang Technologies (HKG:1666) Full Year 2023 Results

Key Financial Results

  • Revenue: CN¥6.77b (up 13% from FY 2022).
  • Net income: CN¥590.2m (up 1.3% from FY 2022).
  • Profit margin: 8.7% (down from 9.7% in FY 2022). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.46 (up from CN¥0.46 in FY 2022).
SEHK:1666 Revenue and Expenses Breakdown April 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tong Ren Tang Technologies EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.1%.

The primary driver behind last 12 months revenue was the The Company segment contributing a total revenue of CN¥4.07b (60% of total revenue). Notably, cost of sales worth CN¥3.93b amounted to 58% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥1.08b (48% of total expenses). Explore how 1666's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 13% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Tong Ren Tang Technologies' balance sheet and an in-depth analysis of the company's financial position.

Valuation is complex, but we're here to simplify it.

Discover if Tong Ren Tang Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.